糖皮质激素性骨质疏松症的预防和治疗进展

糖皮质激素性骨质疏松症的预防和治疗进展

Prevention and Treatment Progress of Glucocorticoid-induced Osteoporosis

ZHANG Pei-guang，LI Zhe-hai，HU He

（Department of Orthopaedics，The Third Affiliated Hospital of Inner Mongolia Medical University，Baotou 0*****，Inner Mongolia，China）

Abstract：For a long time，because of its unique and excellent anti-inflammatory and immune inhibitory effect，glucocorticoid （glucocorticoid，GC）has been widely used insome clinical diseases.Although the application of GC reduces the morbidity and mort ality of many diseases notably ，there are many side effects affecting the patients" metabolism，such as osteoporosis，one of the most serious side effects of long-term GC applications.This article reviewed the prevention and treatment progress of glucocorticoid-induced osteoporosis.

Key words：Glucocorticoid；GIOP；Treatment

糖皮质激素性骨质疏松症（Glucocorticoidinducedosteoporosis，GIOP）是由于内源性或外源性糖皮质激素增加所导致的骨密度下降、骨脆弱增加以及骨折的风险性提高为特征的代谢紊乱性疾病是最为常见的继发性骨质疏松症，易造成的病理性骨折常发生延迟愈合或不愈合，预后极差，致残率极高。然而，GIOP发生机制尚不是十分清楚，因此，对CIOP的预防和治疗意义尤为重要，先就这两方面综述如下。

1 GIOP的预防

研究发现，一些长期服用GC的人群前6个月骨矿密度（bone mineral density，BMD）下降速度最快，随着GC服用时间的延长